Article: Irbesartan

Irbesartan
Systematic (IUPAC) name
2-butyl- 3-[p-(o-1H-tetrazol-5-ylphenyl)benzyl]- 1,3-diazaspiro[4.4]non-1-en-4-one
Identifiers
CAS number	138402-11-6
ATC code	C09CA04
PubChem	3749
DrugBank	APRD00413
Chemical data
Formula	C25H28N6O
Mol. weight	428.53
Pharmacokinetic data
Bioavailability	60–80%
Metabolism	Hepatic (CYP2C9)
Half life	11–15 hours
Excretion	Renal 20%, faecal 65%
Therapeutic considerations
Pregnancy cat.	D (Au)
Legal status	S4 (Au), POM (UK), ℞-only (U.S.)
Routes	Oral

Irbesartan (INN) (IPA: [ɜrbəˈsatən]) is an angiotensin II receptor antagonist used mainly for the treatment of hypertension. Irbesartan was developed by Sanofi Research (now part of Sanofi Aventis). It is jointly marketed by Sanofi Aventis and Bristol-Myers Squibb under the trade names Aprovel, Karvea, and Avapro.

Clinical use

Main article: Angiotensin II receptor antagonist

Indications

As with all angiotensin II receptor antagonists, irbesartan is indicated for the treatment of hypertension. Irbesartan may also delay progression of diabetic nephropathy and is also indicated for the reduction of renal disease progression in patients with type 2 diabetes, hypertension and microalbuminuria (>30 mg/24 hours) or proteinuria (>900 mg/24 hours).^[1]

Combination with diuretic

Irbesartan is also available in a combination formulation with a low dose thiazide diuretic, invariably hydrochlorothiazide, to achieve an additive antihypertensive effect. Irbesartan/hydrochlorothiazide combination preparations are marketed under similar trade names to irbesartan preparations, including CoAprovel, Karvezide and Avapro HCT.